Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis
NCT01846962 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64
Last updated 2018-05-11
Summary
Therapeutic strategies for eosinophilic esophagitis (EoE) actually include: 1) allergen avoidance through dietary modifications, and 2) pharmacologic antiinflammatory therapy. Medical treatment is mainly based on topical administration of corticosteroids by swallowing fluticasone propionate or budesonide spray. Dietetic treatment with highest efficacy is elemental diet, consisting in exclusive feeding with amino-acid based formulas, often administered trough SNG. Alternative choices of acceptable efficacy are empirical six-foods elimination diet (cow's milk, egg, soy, wheat, peanuts, fish) and targeted elimination diet based on the results of allergy tests. Most of the paediatric patients with EE respond to elemental or targeted elimination diets, and therefore such authors recommend elimination diets to be considered the treatment of choice in children. However, elimination diets can often be complex to follow and may be associated with poor adherence owing to the low palatability of a highly restricted diet. In non-compliant patients, especially in adolescents and young adults, it may be more practical to proceed first with corticosteroid treatment. In the case of partial response to elimination diets or corticosteroids, a combination of both treatment mod. However, there has been limited testing of these regimens in randomized controlled trials, while most of available literature is based on case series.
The aim of this study was to compare the efficacy of six-foods elimination diet, swallowed fluticasone, swallowed budesonide and oral viscous budesonide (OVB) in pediatric patients with active EoE. The investigators assessed the effects of randomly assigned treatment on clinical and endoscopic/histologic severity as primary and secondary outcomes, respectively. The investigators describe clinical, allergological, endoscopic and histological features, and pH study results, of our pediatric population.
Conditions
- Eosinophilic Esophagitis
Interventions
- DRUG
-
Budesonide
The administered dose of topical steroid was 400mcg or 800mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
- DRUG
-
Fluticasone
The administered dose of topical steroid was 440mcg or 880mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
- BEHAVIORAL
-
six-foods elimination diet
six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
- DRUG
-
Oral Viscous Budesonide (OVB)
The administered dose of topical steroid was 1mg/day or 2mg/day (\<150 cm or \>150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
Sponsors & Collaborators
-
Azienda Policlinico Umberto I
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 6 Months
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-11-30
- Primary Completion
- 2013-04-30
- Completion
- 2013-06-30
Countries
- Italy
Study Locations
More Related Trials
-
Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis
NCT02434029 ·Status: COMPLETED ·Phase: PHASE3
-
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
NCT06596252 ·Status: RECRUITING ·Phase: PHASE3
-
Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis
NCT02493335 ·Status: COMPLETED ·Phase: PHASE3
-
Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis
NCT02280616 ·Status: COMPLETED ·Phase: PHASE2
-
Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis
NCT00638456 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Flovent in Patients With Eosinophilic Esophagitis
NCT00426283 ·Status: COMPLETED ·Phase: PHASE2
-
Budesonide for Eosinophilic Esophagitis
NCT00271349 ·Status: COMPLETED ·Phase: PHASE2
-
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone
NCT01702701 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders
NCT00266578 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children
NCT05309590 ·Status: ACTIVE_NOT_RECRUITING
-
OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension
NCT01642212 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children
NCT01458418 ·Status: TERMINATED ·Phase: NA
-
Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE)
NCT05214599 ·Status: WITHDRAWN ·Phase: PHASE2
-
Characteristics and Inflammatory Markers in Children with Eosinophilic Esophagitis (EoE)
NCT03980886 ·Status: RECRUITING
-
A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis
NCT01016223 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Esophageal Clearance Times of Oral Budesonide Preparations
NCT02125851 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Efficacy, Safety and Patient' Satisfaction of Therapeutic Switch From Off-Steroids to Budesonide
NCT05594849 ·Status: COMPLETED
-
Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)
NCT03245840 ·Status: TERMINATED ·Phase: PHASE3
-
A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo
NCT01136382 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma
NCT01656811 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)
NCT02736409 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
NCT00079937 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Efficacy and Safety of E004 in Children With Asthma
NCT01460511 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
NCT05083312 ·Status: COMPLETED ·Phase: PHASE3
-
Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge
NCT03369847 ·Status: COMPLETED ·Phase: PHASE4